Well Referenced

Tag: Diabetic Polyneuropathy

A Review of Alternative Treatment Options in Diabetic Polyneuropathy

This 2021 narrative review evaluates non-conventional treatment modalities for diabetic polyneuropathy (DPN), a common yet difficult-to-treat diabetes complication. It discusses pharmacologic and non-pharmacologic alternatives such as topical agents (capsaicin, lidocaine), nutritional supplements (alpha-lipoic acid, benfotiamine, acetyl-L-carnitine), and non-invasive modalities (acupuncture, electrical nerve stimulation). While several of these interventions demonstrated symptom

Read More »
June 26, 2025 No Comments

A Case for Alpha-Lipoic Acid as an Alternative Treatment for Diabetic Polyneuropathy

This 2018 systematic review examined the therapeutic role of alpha-lipoic acid (ALA) in diabetic polyneuropathy (DPN), focusing on efficacy, safety, and cost-effectiveness. Based on 25 studies, including randomized controlled and open-label trials, ALA administered at 600 mg/day—either intravenously or orally—consistently reduced neuropathic symptoms with minimal adverse effects. Mechanistically, ALA exerts

Read More »
June 26, 2025 No Comments

Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features

The study examines the role of alpha-lipoic acid (ALA) in glucose metabolism, emphasizing its antioxidant properties, ability to enhance insulin sensitivity and secretion, and therapeutic potential in conditions like diabetic polyneuropathy, metabolic syndrome, polycystic ovary syndrome (PCOS), and obesity. ALA is widely prescribed for diabetic neuropathy due to its benefits

Read More »
June 26, 2025 No Comments

The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial

The study titled “The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial” (Diabetes Care, 2003, PMID: 12610036) is a randomized controlled trial investigating the effects of alpha-lipoic acid (ALA) on diabetic polyneuropathy. Involving 120 patients with type 2 diabetes and symptomatic polyneuropathy, participants received either

Read More »
June 26, 2025 No Comments

Treatment of Symptomatic Diabetic Polyneuropathy With the Antioxidant Alpha-Lipoic Acid: A Meta-Analysis

The meta-analysis titled “Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis” (Diabet Med, 2004, PMID: 14984445) evaluated the efficacy and safety of intravenous alpha-lipoic acid (600 mg/day) over three weeks in diabetic patients with symptomatic polyneuropathy. Analyzing data from four randomized, double-masked, placebo-controlled trials (n=1,258), the

Read More »
June 26, 2025 No Comments